Vitrolife AB (publ) (STO:VITR)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 14.87B |
| Revenue (ttm) | 3.41B |
| Net Income (ttm) | -5.01B |
| Shares Out | 135.42M |
| EPS (ttm) | -37.01 |
| PE Ratio | n/a |
| Forward PE | 23.97 |
| Dividend | 1.10 (0.97%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 84,167 |
| Average Volume | 287,019 |
| Open | 112.90 |
| Previous Close | 113.50 |
| Day's Range | 109.20 - 112.90 |
| 52-Week Range | 84.60 - 163.10 |
| Beta | 1.76 |
| RSI | 58.54 |
| Earnings Date | Jul 16, 2026 |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Vitrolife AB (VTRLY) Q1 2026 Earnings Call Highlights: Strong North American Growth Amid Middle ...
Vitrolife AB (VTRLY) Q1 2026 Earnings Call Highlights: Strong North American Growth Amid Middle East Challenges
Q1 2026 Vitrolife AB Earnings Call Transcript
Q1 2026 Vitrolife AB Earnings Call Transcript
Vitrolife AB Earnings Call Transcript: Q1 2026
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%, driven by a favorable product mix and strategic focus on profitable segments.
Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies
GOTHENBURG, Sweden, April 23, 2026 /PRNewswire/ -- First quarter Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK. Sales per region, in local currencies,...
Notice of the Annual General Meeting of Vitrolife AB (publ)
GOTHENBURG, Sweden, April 1, 2026 /PRNewswire/ -- The Annual General Meeting of Vitrolife AB (publ), 556354-3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsport...
Vitrolife AB Earnings Call Transcript: Q4 2025
Q4 saw 6% organic growth (excl. discontinued business), with strong Americas and APAC performance, but margins declined due to currency and mix effects. Strategic restructuring in Genetic Services and investments in sales, marketing, and IT aim to drive profitable growth as market conditions normalize in 2026.
Vitrolife AB (publ) - Fourth quarter and full year report 2025
GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ -- Fourth quarter Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local curren...
Invitation to Vitrolife Group's presentation of the fourth quarter and full year report 2025
GOTHENBURG, Sweden, Jan. 20, 2026 /PRNewswire/ -- Vitrolife AB (publ) will publish its fourth quarter and full year report 2025 on Tuesday, 3 February 2026 at 08:00 am CET. A conference call for inves...
Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026
GOTHENBURG, Sweden , Oct. 29, 2025 /PRNewswire/ -- In accordance with the Nomination Committee Charter adopted at the Annual General Meeting 2025, the members who, together with the Chair of the Board...
Vitrolife AB Earnings Call Transcript: Q3 2025
Q3 saw 5% organic growth (excl. discontinued business) and strong cash flow, with Americas leading at 11% growth. Gross margin was stable at 58.9%, but currency headwinds and increased investments reduced EBITDA margin to 30.3%.
Vitrolife AB Earnings Call Transcript: Q2 2025
Q2 2025 delivered 3% organic growth (excl. discontinued), with strong share gains in consumables and genetics, but sales and margins were hit by currency headwinds and increased U.S. investment. Americas and EMEA outperformed their markets, while APAC remained flat due to weak cycles and delayed capital purchases.
Vitrolife AB Earnings Call Transcript: Q1 2025
EMEA and Americas delivered strong growth, offsetting APAC's sharp decline due to high prior-year comps. Gross margin improved, but EBITDA and net income declined year-over-year, mainly from FX and higher selling costs. Strategic focus remains on growth, innovation, and operational efficiency.
Vitrolife AB Earnings Call Transcript: Q4 2024
Q4 2024 saw record sales and margins, driven by strong Consumables and Technologies growth, with operational efficiencies boosting profitability. Regional performance was mixed, and discontinued activities due to sanctions will have a gradual, neutral margin impact.
Vitrolife AB Earnings Call Transcript: Q3 2024
Q3 saw 7% organic growth in local currency, with strong gains in consumables and improved gross margin. Technologies and genetic services showed positive trends, though Genomic kits continued to decline. Management expects continued investment and steady progress toward long-term growth targets.
Vitrolife AB Earnings Call Transcript: Q2 2024
Gross margin rose to 59.9% and EBITDA margin to 34.7%, driven by strong product mix and operational improvements. Sales grew 4% organically, with notable market share gains in media and technologies, and the eFertility acquisition supports strategic growth. Net income and EPS increased, while outlook remains positive for H2.